(CercleFinance.com) – AstraZeneca reports that overall survival (OS) results from a phase III trial favored datopotamab deruxtecan (Dato-DXd) over docetaxel in patients with non-small lung cancer cells (NSCLC) locally advanced or metastatic having received at least one prior line of treatment.
Although survival results did not reach statistical significance in the overall population, a clinically meaningful improvement in OS was observed in patients with non-squamous NSCLC.
These results add to the positive progression-free survival (PFS) data presented at the European Society for Medical Oncology Congress 2023, where datopotamab deruxtecan showed a statistically significant improvement in PFS in the overall population and a clinically meaningful benefit in patients with non-squamous NSCLC.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
